NMTC Stock Forecast 2025-2026
Distance to NMTC Price Targets
NMTC Price Momentum
10 Quality Stocks Worth Considering Now
Researching NeuroOne (NMTC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NMTC and similar high-potential opportunities.
Latest NMTC Stock Price Targets & Analyst Predictions
NMTC has shown a year-to-date change of 6.0% and a 1-year change of -27.3%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for NMTC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NMTC Analyst Ratings
NMTC Price Target Range
Latest NMTC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NMTC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 15, 2023 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $2.20 |
| Mar 28, 2022 | Craig-Hallum | Alexander Nowak | Hold | Downgrade | $0.00 |
| Dec 3, 2021 | Alliance Global Partners | Buy | Initiates | $0.00 | |
| Nov 15, 2021 | Craig-Hallum | Buy | Initiates | $0.00 |
NeuroOne Medical Technologies Corporation (NMTC) Competitors
The following stocks are similar to NeuroOne based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NeuroOne Medical Technologies Corporation (NMTC) Financial Data
NeuroOne Medical Technologies Corporation has a market capitalization of $27.16M with a P/E ratio of -1.9x. The company generates $5.75M in trailing twelve-month revenue with a -125.0% profit margin.
Revenue growth is +234.9% quarter-over-quarter, while maintaining an operating margin of +52.3% and return on equity of -195.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
NeuroOne Medical Technologies Corporation (NMTC) Business Model
About NeuroOne Medical Technologies Corporation
Develops innovative neural surgical solutions.
The company designs and markets advanced electrode technology for recording and stimulating brain activity, generating revenue through sales of these products used in various neurological applications such as EEG and ECoG. By focusing on less invasive and cost-effective solutions, NeuroOne aims to cater to a growing market demand in neurology and neurosurgery.
NeuroOne is headquartered in the United States and seeks to address unmet medical needs, potentially transforming healthcare approaches to neurological disorders through its cutting-edge technology.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
17
CEO
Mr. David A. Rosa M.D.
Country
United States
IPO Year
2017
Website
nmtc1.comNeuroOne Medical Technologies Corporation (NMTC) Latest News & Analysis
Today's Marketplace interviewed NeuroOne Medical Technologies CEO Dave Rosa and Creighton University Nursing Dean Jessica Clark about new epilepsy treatments. The full interview is available online.
The interview highlights NeuroOne's advancements in epilepsy treatments, potentially boosting investor confidence and interest in NMTC's growth prospects.
NeuroOne Medical Technologies (Nasdaq: NMTC) announced CEO Dave Rosa's appearance on Today's Marketplace, discussing advancements in surgical care for neurological disorders.
CEO media appearances can enhance a company's visibility and credibility, potentially attracting investors and increasing stock interest in NeuroOne Medical Technologies.
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace - Update
9 days agoNeuroOne Medical Technologies (Nasdaq: NMTC) CEO Dave Rosa discussed advancements in epilepsy treatment and the OneRF® Ablation System on Today's Marketplace, highlighting the company's focus on neurological care.
NeuroOne's CEO discussing advancements in epilepsy treatment and their OneRF® Ablation System could boost investor confidence and interest, potentially impacting stock performance positively.
NeuroOne Medical Technologies plans to submit a 510(k) application to the FDA for trigeminal nerve ablation using its OneRF® Technology by May 2025, accelerating its timeline.
Accelerating the FDA submission timeline could enhance NeuroOne's market position and potential revenue from new treatments, impacting stock performance and investor sentiment.
NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
22 days agoNeuroOne Medical Technologies (NASDAQ: NMTC) will participate in the Oppenheimer 35th Annual Healthcare Conference on March 19, 2025, focusing on surgical solutions for neurological disorders.
NeuroOne's participation in a prominent healthcare conference highlights its commitment to innovation in neurology, potentially attracting investor interest and affecting stock performance.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will hold its Q1 2025 earnings conference call on February 12, 2025, at 8:30 AM ET. Key participants include CEO Dave Rosa and CFO Ron McClurg.
NeuroOne's Q1 2025 earnings call will provide insights into financial performance and future strategies, impacting investor sentiment and stock valuation.
Frequently Asked Questions About NMTC Stock
What is NeuroOne Medical Technologies Corporation's (NMTC) stock forecast for 2025?
Analyst forecasts for NeuroOne Medical Technologies Corporation (NMTC) are not currently available. The stock is trading at $0.88.
Is NMTC stock a good investment in 2025?
Analyst ratings for NMTC are not currently available. The stock is currently trading at $0.88. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NMTC stock?
Price predictions from Wall Street analysts for NMTC are not currently available. The stock is trading at $0.88.
What is NeuroOne Medical Technologies Corporation's business model?
The company designs and markets advanced electrode technology for recording and stimulating brain activity, generating revenue through sales of these products used in various neurological applications such as EEG and ECoG. By focusing on less invasive and cost-effective solutions, NeuroOne aims to cater to a growing market demand in neurology and neurosurgery.
What is the highest forecasted price for NMTC NeuroOne Medical Technologies Corporation?
Price targets from Wall Street analysts for NMTC are not currently available. The stock is trading at $0.88.
What is the lowest forecasted price for NMTC NeuroOne Medical Technologies Corporation?
Price targets from Wall Street analysts for NMTC are not currently available. The stock is trading at $0.88.
What is the overall NMTC consensus from analysts for NeuroOne Medical Technologies Corporation?
Analyst ratings for NMTC are not currently available. The stock is trading at $0.88.
How accurate are NMTC stock price projections?
Stock price projections, including those for NeuroOne Medical Technologies Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
